Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$37.26 -4.0%	$36.82	$23.42 ▼ $62.58	$2.16B	0.8	706,532 shs	699,664 shs
ANAB AnaptysBio	$20.10 -0.6%	$23.64	$12.21 ▼ $40.70	$562.74M	-0.2	755,335 shs	206,440 shs
DNLI Denali Therapeutics	$15.57 +0.5%	$14.31	$10.57 ▼ $33.33	$2.28B	1.36	1.42 million shs	1.39 million shs
OCUL Ocular Therapeutix	$11.87 -3.5%	$10.91	$5.78 ▼ $12.91	$2.07B	1.49	1.79 million shs	903,074 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+4.84%	-3.00%	+30.20%	-16.05%
ANAB AnaptysBio	0.00%	+0.40%	-24.94%	-1.08%	-46.44%
DNLI Denali Therapeutics	0.00%	+5.37%	+13.31%	+15.42%	-37.46%
OCUL Ocular Therapeutix	0.00%	-2.54%	+0.74%	+68.49%	+35.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3694 of 5 stars	3.4	2.0	4.3	2.9	0.8	1.9
ANAB AnaptysBio	3.0024 of 5 stars	4.4	0.0	0.0	2.7	2.5	0.6
DNLI Denali Therapeutics	4.2127 of 5 stars	3.6	1.0	4.7	3.2	3.3	0.0
OCUL Ocular Therapeutix	4.0761 of 5 stars	3.5	3.0	4.1	3.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	51.19% Upside
ANAB AnaptysBio	2.80	Moderate Buy	$46.13	129.48% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	115.90% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.20	44.90% Upside

Current Analyst Ratings Breakdown

Latest ANAB, OCUL, AGIO, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/12/2025	ANAB AnaptysBio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $20.00
8/7/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $45.00
8/6/2025	OCUL Ocular Therapeutix	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$22.00 ➝ $20.00
8/5/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2025	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $80.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	59.31	N/A	N/A	$27.02 per share	1.38
ANAB AnaptysBio	$123.16M	4.57	N/A	N/A	$2.33 per share	8.63
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	$8.53 per share	N/A
OCUL Ocular Therapeutix	$56.66M	36.45	N/A	N/A	$2.01 per share	5.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.39	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
ANAB AnaptysBio	-$145.23M	-$4.48	N/A	N/A	N/A	-107.66%	-366.98%	-30.58%	11/4/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.28	N/A	N/A	N/A	-382.51%	-71.92%	-49.36%	11/13/2025 (Estimated)

Latest ANAB, OCUL, AGIO, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/6/2025	Q2 2025	ANAB AnaptysBio	-$1.50	-$1.34	+$0.16	-$1.34	$11.55 million	$22.26 million
8/5/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	-$0.39	-$0.04	-$0.39	$13.12 million	$13.46 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
ANAB AnaptysBio	N/A	8.22	8.22
DNLI Denali Therapeutics	0.01	10.27	10.27
OCUL Ocular Therapeutix	0.23	10.10	10.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ANAB AnaptysBio	N/A
DNLI Denali Therapeutics	92.92%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
ANAB AnaptysBio	33.50%
DNLI Denali Therapeutics	12.50%
OCUL Ocular Therapeutix	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.24 million	Optionable
ANAB AnaptysBio	100	28.00 million	18.62 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
OCUL Ocular Therapeutix	230	174.00 million	169.99 million	Optionable

ANAB, OCUL, AGIO, and DNLI Headlines

Recent News About These Companies

EntryPoint Capital LLC Purchases New Shares in Ocular Therapeutix, Inc. $OCUL

August 24 at 5:36 AM | marketbeat.com

Deutsche Bank AG Sells 197,895 Shares of Ocular Therapeutix, Inc. $OCUL

August 24 at 3:28 AM | marketbeat.com

Which Is a Better Investment, Ocular Therapeutix, Inc. or Organon & Co. Stock?

August 20, 2025 | aaii.comA

Ocular Hypertension Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

August 15, 2025 | theglobeandmail.com

Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI

August 13, 2025 | ophthalmologytimes.comO

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR

August 13, 2025 | taiwannews.com.twT

Ocular Therapeutix (NASDAQ:OCUL) Hits New 52-Week High - Should You Buy?

August 12, 2025 | marketbeat.com

Equities Analysts Offer Predictions for OCUL Q3 Earnings

August 9, 2025 | marketbeat.com

Q3 EPS Forecast for Ocular Therapeutix Reduced by Analyst

August 9, 2025 | marketbeat.com

Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress

August 8, 2025 | theglobeandmail.com

Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter Report

August 8, 2025 | uk.finance.yahoo.com

Ocular Therapeutix (NASDAQ:OCUL) Price Target Lowered to $20.00 at Scotiabank

August 7, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Price Target Raised to $15.00

August 7, 2025 | marketbeat.com

Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

August 6, 2025 | theglobeandmail.com

Ocular Therapeutix Inc (OCUL) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 6, 2025 | finance.yahoo.com

Which Is a Better Investment, Amneal Pharmaceuticals, Inc. or Ocular Therapeutix, Inc. Stock?

August 6, 2025 | aaii.comA

Ocular Therapeutix (NASDAQ:OCUL) Releases Earnings Results, Misses Expectations By $0.04 EPS

August 6, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down Following Weak Earnings

August 6, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript

August 6, 2025 | insidermonkey.com

OCUL Sales Drop 18%

August 5, 2025 | fool.com

Ocular Therapeutix tumbles as Q2 results miss estimates

August 5, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, OCUL, AGIO, and DNLI Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$37.26 -1.54 (-3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$37.04 -0.21 (-0.58%)

As of 04:47 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AnaptysBio NASDAQ:ANAB

$20.10 -0.12 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$20.20 +0.10 (+0.50%)

As of 04:47 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Denali Therapeutics NASDAQ:DNLI

$15.57 +0.08 (+0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$15.57 0.00 (-0.01%)

As of 05:12 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$11.87 -0.43 (-3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$12.12 +0.25 (+2.10%)

As of 04:55 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time